Streetwise Reports' Article Archives — July 2016 back to current month (2)
Under the guidance of newly appointed president Kenneth Efird, Nobilis Health Corp. plans to continue to roll out new products and optimize its marketing strategy.
Oxycodone is a powerful and lucrative painkiller, but one with serious downsides. Dependency on the opioid has become a major issue medically, politically and, most profoundly, for the patients whose addictions have become debilitating or fatal. DURECT Corp.'s Remoxy, an abuse-deterrent formulation of oxycodone, has an FDA approval date of Sept. 25, 2016, and may provide a safer alternative.
|"Data from DRRX's DUR-928 trial in AH showed meaningful improvements."|
|"PMN's stock is now showing signs that it is ready to advance anew."|
|"This looks like an excellent point to buy back VIV."|